Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab′ fragment (99mTc-DI-DD3B6/22-80B3): results of a phase I trial

  • David MacfarlaneEmail author
  • Angelides Socrates
  • Paul Eisenberg
  • George Larcos
  • Paul Roach
  • Michael Gerometta
  • Richard Smart
  • Wendy Tsui
  • Andrew M. Scott
Original Article



99mTc-DI-DD3B6/22-80B3 (ThromboView®, hereafter abbreviated to 99mTc-DI-80B3 Fab′) is a radiolabelled humanised monoclonal Fab′ fragment with affinity and specificity for D-dimer domains of cross-linked fibrin. Detection of thromboembolic events has been demonstrated in canine models. The study objectives were evaluation of safety and characterisation of biodistribution, immunogenicity and pharmacokinetic profile of increasing doses of 99mTc-DI-80B3 Fab′ in subjects with acute lower-limb DVT.


Twenty-six patients with acute lower limb DVT were enrolled. Of these, 21 received a single intravenous dose of 0.5 mg (n = 6), 1.0 mg (n = 9) or 2 mg (n = 6) 99mTc-DI-80B3 Fab′. Blood and urine samples and gamma camera images were collected to 24 h after administration for pharmacokinetic and dosimetry analysis. Vital signs, electrocardiography, hematological and biochemical data and human anti-human antibody (HAHA) levels were monitored for up to 30 days following administration. Patients were assigned to either planar or single photon emission computed tomographic (SPECT) imaging of the thorax at 4 h following injection.


Thirty-five adverse events were reported in 15 of the 21 subjects. Those deemed possibly related to administration of 99mTc-DI-80B3 Fab′ included mild hypertension, mild elevation of LD (lactate dehydrogenase) and moderate elevation of ALT (alanine transaminase). HAHA assays remained negative. Pharmacokinetics and organ dosimetry were comparable to prior normal volunteer data. Localisation of Thromboview® to sites of known thrombus was evident as early as 30 min post-injection.


In subjects with acute DVT, 99mTc-DI-80B3 Fab′ was well tolerated with favourable characteristics for the detection of acute venous thrombosis.


Technetium chemistry Technetium radiopharmaceuticals Radiolabelled proteins–peptides Pulmonary embolism Molecular imaging 



The authors acknowledge the assistance of Prof. SP Butler of St. George Hospital, Sydney, Australia in the recruitment of patients.

Conflict of interest

AGEN Biomedical Limited sponsored and financially supported this trial. Dr. Macfarlane and Prof. Scott were the principal investigators during the study. Dr. Macfarlane currently acts as a consultant to AGEN Biomedical Limited for product and protocol development. Professor Eisenberg is also a consultant to AGEN Biomedical Limited and Dr. Gerometta is an employee of AGEN Biomedical Limited. Wendy Tsui is employed by the University of New South Wales under a research contract between AGEN Biomedical Limited and the university. Professor Scott currently serves as a consultant to Agen Biomedical Limited.


  1. 1.
    Douketis J, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279:458–62.PubMedCrossRefGoogle Scholar
  2. 2.
    Tovey C, Wyatt S. Diagnosis, investigation, and management of deep vein thrombosis. BMJ 2003;326:1180–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Silverstein MD, Heit JA, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population based study. Arch Intern Med 1998;158:585–93.PubMedCrossRefGoogle Scholar
  4. 4.
    White RH. The epidemiology of venous thromboembolism. Circulation 2003;107(Suppl 1):I4–8.PubMedGoogle Scholar
  5. 5.
    Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med 2004;351:268–77.PubMedCrossRefGoogle Scholar
  6. 6.
    Kearon C, Julian JA, Ginsberg JS. Noninvasive diagnosis of deep vein thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 1998;128:663–77.PubMedGoogle Scholar
  7. 7.
    Kearon C. Diagnosis of pulmonary embolism. CMAJ 2003;168:183–94.PubMedGoogle Scholar
  8. 8.
    Lisbona R, Derbekyan V, Novales-Diaz JA, Rush CL. Tc-99m red blood cell venography in deep venous thrombosis of the lower limb: an overview. Clin Nucl Med 1985;10:208–24.PubMedCrossRefGoogle Scholar
  9. 9.
    Lister-James J, Knight LC, Maurer AH, Bush LR, Moyer BR, Dean RT. Thrombus imaging with a technetium-99 m-labeled, activated platelet receptor-binding peptide. J Nucl Med 1996;37:775–81.PubMedGoogle Scholar
  10. 10.
    Rylatt DB, Blake AS, Cottis LE, Massingham DA, Fletcher WA, Masci PP, et al. An immunoassay for human D dimer using monoclonal antibodies. Thromb Res 1983;31:767–78.PubMedCrossRefGoogle Scholar
  11. 11.
    Walker KZ, Milner LJ, Bautovich GJ, Borham P, Wood AK, Rylatt DB, et al. Detection of experimental thrombi in rabbits with an I-labeled fibrin-specific monoclonal antibody. Eur J Nucl Med 1990;16:787–94.PubMedCrossRefGoogle Scholar
  12. 12.
    Walker KZ, Boniface GR, Phippard AF, Harewood W, Bautovich GJ, Bundesen PG. Preclinical evaluation of 99m-technetium-labeled DD-3B6/22 Fab′ for thrombus detection. Thromb Res 1991;64:691–701.PubMedCrossRefGoogle Scholar
  13. 13.
    Bautovich G, Angelides S, Lee FT, Greenough R, Bundesen P, Murray P, et al. Detection of deep venous thrombi and pulmonary embolus with technetium-99m-DD-3B6/22 antifibrin monoclonal antibody Fab′ fragment. J Nucl Med 1994;35:195–202.PubMedGoogle Scholar
  14. 14.
    Morris TA, Marsh JJ, Chiles PG, Konopka RG, Pedersen CA, Schmidt PF, et al. Single photon emission computed tomography of pulmonary emboli and venous thrombi using anti-Ddimer. Am J Respir Crit Care Med 2004;169:987–93.PubMedCrossRefGoogle Scholar
  15. 15.
    Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40(Suppl):37–61.Google Scholar
  16. 16.
    McKay E. A software tool for specifying voxel models for dosimetry estimation. Cancer Biother Radiopharm 2003;18:379–92.PubMedCrossRefGoogle Scholar
  17. 17.
    Macfarlane DJ, Smart RC, Tsui W, Gerometta M, Eisenberg PR, Scott AM. Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab′. Eur J Nucl Med Mol Imaging 2006;33(6):648–56.PubMedCrossRefGoogle Scholar
  18. 18.
    Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538–46.PubMedGoogle Scholar
  19. 19.
    Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689–94.PubMedGoogle Scholar
  20. 20.
    Shen S, DeNardo GL, Sgouros G, O’Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med 1999;40:2102–6.PubMedGoogle Scholar
  21. 21.
    Temple R. Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006;15(4):241–3.PubMedCrossRefGoogle Scholar
  22. 22.
    Carlson MK, Gleason PP, Sen S. Elevation of hepatic transaminases after enoxaparin use: case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. Pharmacotherapy 2001;21(1):108–13.PubMedCrossRefGoogle Scholar
  23. 23.
    Meignan M, Rosso J, Gauthier H, Brunengo F, Claudel S, Sagnard L, d’Azemar P, Simonneau G, Charbonnier B. Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. Arch Intern Med 2000;160(2):159–64.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • David Macfarlane
    • 1
    Email author
  • Angelides Socrates
    • 2
    • 3
    • 4
  • Paul Eisenberg
    • 5
  • George Larcos
    • 2
    • 3
    • 4
  • Paul Roach
    • 2
    • 6
  • Michael Gerometta
    • 7
  • Richard Smart
    • 8
    • 9
  • Wendy Tsui
    • 8
    • 9
  • Andrew M. Scott
    • 10
    • 11
  1. 1.School of MedicineUniversity of QueenslandBrisbaneAustralia
  2. 2.Department of MedicineUniversity of SydneySydneyAustralia
  3. 3.Department of Nuclear Medicine and UltrasoundWestmead HospitalWestmeadAustralia
  4. 4.Centre for Biomedical Imaging and ResearchWestmead HospitalWestmeadAustralia
  5. 5.Amgen IncThousand OaksUSA
  6. 6.Nuclear MedicineRoyal North Shore HospitalSt. LeonardsAustralia
  7. 7.Agen Biomedical Pty LtdBrisbaneAustralia
  8. 8.Nuclear Medicine DepartmentSt. George HospitalSydneyAustralia
  9. 9.Department of MedicineUniversity of New South WalesSydneyAustralia
  10. 10.Centre for PETAustin HospitalMelbourneAustralia
  11. 11.Ludwig InstituteMelbourneAustralia

Personalised recommendations